07:56 AM EST, 03/04/2025 (MT Newswires) -- Natera ( NTRA ) said Tuesday that the US Patent and Trademark Office has issued the company a patent for testing single nucleotide variants in circulating-tumor DNA.

The company said the patent relates to certain methods of preparation for tumor-informed ctDNA monitoring using whole exome or whole genome sequencing and describes various modes of target enrichment in plasma.

Natera ( NTRA ) said the patent adds to its portfolio of molecular residual disease testing patents for whole exome and whole genome sequencing.

Shares of Natera ( NTRA ) were down 1.5% in recent premarket activity.